Development of a UV visible spectrophotometric method for simultaneous estimation of Ranolazine and Metoprolol

Abstract

Ranolazine being Na+ channel blocker agent, decreases the chances of angina attacks. Metoprolol exerts specific β1 blocking effect which results into decreased cardiac contractility and heart Rate (1). Ultimately reduces oxygen demand of heart. Metoprolol enhances the pharmacological activity of Ranolazine so the combination gives better therapeutic activity (2).


There is no UV visible method present for the simultaneous estimation of Ranolazine and Metoprolol. To formulate and evaluate such a formulation involving mentioned drugs this simultaneous equation method was developed using 0.1 N HCl as a solvent. Chosen wavelengths were 272 nm and 242 nm for Ranolazine and Metoprolol Succinate respectively. Linearity range was seen to be 7.5 to 40 ppm for Ranolazine and 1 to 5 ppm for Metoprolol. Recovery studies and Validation were successfully performed according to ICH guidelines. This method can be applied for any formulation consisting mentioned drugs without interference of other excipients.


Keywords: UV visible spectrophotometry, Simultaneous estimation, Ranolazine, Metoprolol succinate, Analytical Method development, Angina Pectoris

Keywords: UV visible spectrophotometry, Simultaneous estimation, Ranolazine, Metoprolol succinate, Analytical Method development, Angina Pectoris

Downloads

Download data is not yet available.

Author Biographies

Krupa Hareshbhai Vyas, Assistant Professor, Khyati College of Pharmacy, Ahmedabad, Gujarat, India

Assistant Professor, Khyati College of Pharmacy, Ahmedabad, Gujarat, India

Moinuddin Soniwala, B. K. Modi Government Pharmacy College, Rajkot, Gujarat, India

B. K. Modi Government Pharmacy College, Rajkot, Gujarat, India

Amit Vyas, B. K. Modi Government Pharmacy College, Rajkot, Gujarat, India

B. K. Modi Government Pharmacy College, Rajkot, Gujarat, India

Nirav Shah, SAL Institute of Pharmacy, Ahmedabad, Gujarat, India

SAL Institute of Pharmacy, Ahmedabad, Gujarat, India

References

1. Imperi GA, Lambert CR, Coy K, Lopez L, Pepine CJ: Effects of titrated beta blockade (metoprolol) on silent myocardial ischemia in ambulatory patients with coronary artery disease. Am J Cardiol. 1987; 60(7):519-24. https://doi.org/10.1016/0002-9149(87)90297-9
2. Tavazzi L: Ranolazine, a new antianginal drug. Future Cardiol. 2005; 1(4):447-455. https://doi.org/10.2217/14796678.1.4.447
3. Sossalla S, Maier LS. Role of Ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol. Ther. 2012; 133(3):311-323. https://doi.org/10.1016/j.pharmthera.2011.11.003
4. Poornima K, Kp C. Development and Validation of RP-HPLC Method for Estimation of Metoprolol and Ranolazine in Bulk and in Formulation. J. Chron. Ther. Drug Deliv. 2015; 6(2): 41–8.
5. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, et al. Ranolazine combined with Enalapril or Metoprolol prevents progressive LV dysfunction and re-modelling in dogs with moderate heart failure. Am. J. physiol. Heart circ. 2008; 295(5):2149-55 https://doi.org/10.1152/ajpheart.00728.2008
6. Drug profile Ranolazine, https://pubchem.ncbi.nlm.nih.gov/compound/ranolazine.
7. https://www.drugbank.ca/drugs/DB00243.
8. Drug profile Metoprolol succinate, https://pubchem.ncbi.nlm.nih.gov/compound/metoprolol.
9. https://www.drugbank.ca/drugs/DB00264.
10. ICH guidelines for analytical method validation
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_ R1/Step4/Q2_R1 Guideline.pdf.
Statistics
46 Views | 6 Downloads
How to Cite
1.
Vyas K, Soniwala M, Vyas A, Shah N. Development of a UV visible spectrophotometric method for simultaneous estimation of Ranolazine and Metoprolol. JDDT [Internet]. 15Jun.2022 [cited 1Jul.2022];12(3-S):64-2. Available from: https://jddtonline.info/index.php/jddt/article/view/5481